Advanced search
Publication Cover
International Medical Case Reports Journal Volume 17, 2024 - Issue
Submit an article Journal homepage
80
Views
0
CrossRef citations to date
0
Altmetric
Case Reports

Lethal Immune Myocarditis and Myasthenia Gravis Due to Anti-PD-1 Treatment for a Bladder Cancer Patient: A Case Report and Possible Treatment Inspiration

Pan Gao1 Department of Urology, Second People’s Hospital of Yichang, Yichang, Hubei Province, People’s Republic of China;2 Department of Urology, Second People’s Hospital of China Three Gorges University, Yichang, Hubei Province, People’s Republic of ChinaORCID Iconhttps://orcid.org/0000-0003-4314-7929
ORCID Icon,
Xinyu Li1 Department of Urology, Second People’s Hospital of Yichang, Yichang, Hubei Province, People’s Republic of China;2 Department of Urology, Second People’s Hospital of China Three Gorges University, Yichang, Hubei Province, People’s Republic of China
,
Ziqiu He1 Department of Urology, Second People’s Hospital of Yichang, Yichang, Hubei Province, People’s Republic of China;2 Department of Urology, Second People’s Hospital of China Three Gorges University, Yichang, Hubei Province, People’s Republic of China
,
Hongbo Zhang1 Department of Urology, Second People’s Hospital of Yichang, Yichang, Hubei Province, People’s Republic of China;2 Department of Urology, Second People’s Hospital of China Three Gorges University, Yichang, Hubei Province, People’s Republic of China
,
Zhi Zhang1 Department of Urology, Second People’s Hospital of Yichang, Yichang, Hubei Province, People’s Republic of China;2 Department of Urology, Second People’s Hospital of China Three Gorges University, Yichang, Hubei Province, People’s Republic of China
&
Zonglai Liu1 Department of Urology, Second People’s Hospital of Yichang, Yichang, Hubei Province, People’s Republic of China;2 Department of Urology, Second People’s Hospital of China Three Gorges University, Yichang, Hubei Province, People’s Republic of ChinaCorrespondence[email protected]
Pages 359-365 | Received 05 Dec 2023, Accepted 04 Apr 2024, Published online: 17 Apr 2024

References

  • Siegel RL, Giaquinto AN, Jemal A. Cancer statistics, 2024. CA Cancer J Clin. 2024;74(1):12–49. doi:10.3322/caac.21820
  • Soria F, Shariat SF, Lerner SP, et al. Epidemiology, diagnosis, preoperative evaluation and prognostic assessment of upper-tract urothelial carcinoma (UTUC). World J Urol. 2017;35(3):379–387. doi:10.1007/s00345-016-1928-x
  • Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209–249. doi:10.3322/caac.21660
  • Meeks J, Black P, Galsky M, et al. Checkpoint inhibitors in urothelial carcinoma-future directions and biomarker selection. Europ Urol. 2023;84(5):473–483. doi:10.1016/j.eururo.2023.05.011
  • Moslehi J, Salem J, Sosman J, et al. Increased reporting of fatal immune checkpoint inhibitor-associated myocarditis. Lancet. 2018;391(10124):933. doi:10.1016/S0140-6736(18)30533-6
  • Bonaca M, Olenchock B, Salem J, et al. Myocarditis in the setting of cancer therapeutics: proposed case definitions for emerging clinical syndromes in cardio-oncology. Circulation. 2019;140(1):80–91. doi:10.1161/CIRCULATIONAHA.118.034497
  • Wang D, Salem J, Cohen J, et al. Fatal toxic effects associated with immune checkpoint inhibitors: a systematic review and meta-analysis. JAMA Oncol. 2018;4(12):1721–1728. doi:10.1001/jamaoncol.2018.3923
  • Axelrod M, Meijers W, Screever E, et al. T cells specific for α-myosin drive immunotherapy-related myocarditis. Nature. 2022;611(7937):818–826. doi:10.1038/s41586-022-05432-3
  • Dong H, Qi Y, Kong X, et al. PD-1/PD-L1 inhibitor-associated myocarditis: epidemiology, characteristics, diagnosis, treatment, and potential mechanism. Front Pharmacol. 2022;13:835510. doi:10.3389/fphar.2022.835510
  • Salem J, Manouchehri A, Moey M, et al. Cardiovascular toxicities associated with immune checkpoint inhibitors: an observational, retrospective, pharmacovigilance study. Lancet Oncol. 2018;19(12):1579–1589. doi:10.1016/S1470-2045(18)30608-9
  • Liang S, Yang J, Lin Y, et al. Immune myocarditis overlapping with myasthenia gravis due to anti-PD-1 treatment for a chordoma patient: a case report and literature review. Front Immunol. 2021;12:682262. doi:10.3389/fimmu.2021.682262
  • Ferreira V, Schulz-Menger J, Holmvang G, et al. Cardiovascular magnetic resonance in nonischemic myocardial inflammation: expert recommendations. J Am Coll Cardiol. 2018;72(24):3158–3176. doi:10.1016/j.jacc.2018.09.072
  • Zhang L, Awadalla M, Mahmood S, et al. Cardiovascular magnetic resonance in immune checkpoint inhibitor-associated myocarditis. Eur Heart J. 2020;41(18):1733–1743. doi:10.1093/eurheartj/ehaa051
  • Ji C, Roy M, Golas J, et al. Myocarditis in cynomolgus monkeys following treatment with immune checkpoint inhibitors. Clin Cancer Res. 2019;25(15):4735–4748. doi:10.1158/1078-0432.CCR-18-4083
  • Ganatra S, Neilan T. Immune checkpoint inhibitor-associated myocarditis. Oncologist. 2018;23(8):879–886. doi:10.1634/theoncologist.2018-0130
  • Thompson J, Schneider B, Brahmer J, et al. Management of immunotherapy-related toxicities, version 1.2022, NCCN clinical practice guidelines in oncology. J National Compr Cancer Network. 2022;20(4):387–405. doi:10.6004/jnccn.2022.0020
  • Liu Z, Fan Y, Guo J, et al. Fulminant myocarditis caused by immune checkpoint inhibitor: a case report and possible treatment inspiration. ESC Heart Fail. 2022;9(3):2020–2026. doi:10.1002/ehf2.13912
  • Curigliano G, Lenihan D, Fradley M, et al. Management of cardiac disease in cancer patients throughout oncological treatment: ESMO consensus recommendations. Ann Oncol. 2020;31(2):171–190. doi:10.1016/j.annonc.2019.10.023

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.